AstraZeneca PLC (AZN) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

Total Assets Chart for AstraZeneca PLC

AstraZeneca PLC (AZN) total assets for FY2025 were GBP 114.1B, a 9.6% change from FY2024. AstraZeneca PLC's total assets grew from GBP 6.1B in 1990 to GBP 114.1B in 2025 (1769.7% over 35 years). Total assets compound annual growth rate: 5-year CAGR of 11.3%, 10-year CAGR of 6.6%, 20-year CAGR of 7.9%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (British Pounds)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
£177.73B
Implied Share Price
£114.60
Enterprise Value
£197.95B
Revenue (TTM)
£61.37B
EBITDA
£19.90B
Profit Margin
17.02%
Trailing P/E
23.15
Forward P/E
15.08
Price/Book (MRQ)
4.77
Price/Sales (TTM)
2.90
EV/EBITDA
13.12
EV/Revenue
4.35
Dividend Yield
2.76%
Book Value
£24.04
Free Cash Flow (FY2025)
£8.67B
Free Cash Flow Yield
4.88%

Snapshot as of 15th August 2026 — not point-in-time controlled, may lag the live market by a few days.